Boston Scientific Co. (NYSE:BSX) Stock Holdings Increased by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. lifted its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 7.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,684 shares of the medical equipment provider's stock after purchasing an additional 4,130 shares during the quarter. TD Waterhouse Canada Inc.'s holdings in Boston Scientific were worth $5,153,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of BSX. TFC Financial Management Inc. increased its stake in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 210 shares during the period. Global Wealth Strategies & Associates boosted its holdings in shares of Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 250 shares in the last quarter. West Oak Capital LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at approximately $29,000. Valley National Advisers Inc. raised its holdings in Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 286 shares in the last quarter. Finally, Fairway Wealth LLC acquired a new stake in Boston Scientific in the fourth quarter worth approximately $36,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

BSX stock opened at $94.96 on Wednesday. The stock has a market cap of $140.45 billion, a P/E ratio of 75.97, a P/E/G ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a 50 day simple moving average of $99.00 and a 200 day simple moving average of $94.55. Boston Scientific Co. has a 52 week low of $67.80 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on BSX. Needham & Company LLC raised Boston Scientific from a "hold" rating to a "buy" rating and set a $113.00 price objective on the stock in a research note on Wednesday, April 16th. Barclays boosted their price target on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Piper Sandler upped their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Raymond James lifted their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Finally, Wells Fargo & Company increased their target price on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and a consensus price target of $110.22.

Insider Activity

In related news, CFO Daniel J. Brennan sold 15,087 shares of Boston Scientific stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the completion of the sale, the chief financial officer now owns 241,451 shares of the company's stock, valued at approximately $25,369,256.57. The trade was a 5.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 138,009 shares of company stock worth $14,407,381 in the last three months. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.